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Executive Summary 
The marketing of GM salmon will lower salmon prices and increase consumption of 
salmon, an exceptionally good source of omega-3 fatty acids linked to lower risk of heart 
disease.  We estimate that the resulting increase in omega-3 intake will prevent between 
600 and 2600 deaths per year in the U.S. 1 
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Researchers are busy assessing possible adverse health and environmental risks of 
genetically modified (GM) foods in accordance with European Union directives 
(European Executive Council, 2000), international agreements (Convention on 
Biodiversity, 2000), and U.S. regulatory policy (U.S. Food and Drug Administration, 
1992).  GM foods may offer great benefits, both directly as with nutritionally superior 
“Golden Rice” (Ye, 2000), and indirectly through improved diets, but regulators do not 
formally consider such benefits in their decision-making (European Executive Council, 
2000, U.S. Food and Drug Administration, 1992).  
The case of GM salmon illustrates both the potential magnitude of the health 
benefits from indirect nutritional improvements and the problem with the regulators’ 
generally one-sided approach, which is ultimately derived from the “precautionary 
principle.” The protein to genetically modify salmon is now under review by the Food 
and Drug Administration’s (FDA) Center for Veterinary Medicine, which is considering 
its safety and efficacy as an animal drug, and is consulting with other agencies on risks to 
salmon protected by the Endangered Species Act. Apparently excluded from the 
regulatory calculus is the substantial effect of GM salmon on reducing the risk of 
coronary heart disease (CHD), the number one cause of death in the U.S (National Center 
for Health Statistics, 2000).  
By growing year-round, GM salmon can reduce fish farmers’ costs.  Lower 
production costs would lower prices, increase salmon consumption, and boost intake of 2 
 omega three (n-3) fatty acids.  These fatty acids significantly lower the risks of CHD and other 
health problems (Rosenberg, 2002).   
Rational policy requires regulators to carefully compare the risks and the benefits of GM 
food.  A small number of GM salmon, if accidentally released and not previously sterilized, 
could threaten a local species by creating hybrid offspring (National Research Council, 2000).  
A sensible evaluation of these risks must involve some comparison with the full social benefits 
of GM salmon.  These are likely to range from economic gains to fish farmers to effects on 
consumer’s health.   
To illustrate the importance of a frequently neglected category of benefits from GM 
foods--improved nutrition--we estimate declines in heart attacks from GM salmon by focusing 
on four factors (1). 
 They represent the effects of 1) n-3 fatty acid intake on heart disease risk, 2) 
salmon consumption on n-3 intake, 3) salmon prices on salmon consumption, and 4) farming 
costs on salmon retail prices.  We estimate that GM salmon would prevent between 600 and 
2600 deaths in the U.S. annually, with a best estimate of roughly 1,400.   
Health Effects  
Omega three fatty acids can reduce risks of fatal cardiac arrest.  Two long chained 
highly polyunsaturated fatty acids, docosahexaenoic acid (DHA, 22:6 n-3) and eicosapentaenoic 
acid (EPA, 20:5 n-3), are thought to have this benefit because they provide strong 
antiarrhythmic action on the heart, serving as precursors to prostaglandins, and providing anti-
inflammatory and anti-thrombotic actions.   
Recent studies confirm earlier research that n-3 intake lowers the risk from CHD for 
men and women of varying health.  A study of 11,323 survivors of myocardial infarction found    3
  
   
that a randomly assigned dose of one gram per day reduced the risk of sudden death by half 
within 4 to 8 months (GISSI, 2002).  Albert et al. found that n-3 fatty acids in fish are strongly 
associated with a reduced risk of sudden death among men without prior evidence of cardio-
vascular disease (Albert et al., 2002). Hu et al. report a significant relationship between n-3 fatty 
acid intake and the relative risk of fatal CHD among women without previous diagnoses of 
CHD or cancer (Hu et al., 2002).   
As Hu et al. show that risk varies nonlinearly with n-3 intake (Hu et al., 2002), we 
estimate that a one percent increase in n-3 intake lowers CHD fatalities by .29 percent by fitting 
an exponential function.  See Figure 1.  
Figure 1
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Note: We present Hu et al.’s (2002) point estimates of relative risk and the 95 percent confidence limits 
as ♦ and ■ respectively.   
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Intake of n-3 fatty acids may also protect against health conditions that we choose not to 
quantify, including rheumatoid arthritis and asthma (Calder et al., 2002), epileptic seizure 
(Schlanger  et al., 2002), endometrial cancer (Terry et al., 2002), age-related macular 
degeneration (Seddon et al., 2001), prostate cancer (Terry et al., 2001), and premature birth  
(Allen  & Harris, 2001).  These benefits exist despite generally smaller risks from contaminants 
like mercury and dioxin (Egeland & Middaugh, 1997). 
Nutritional Effects  
We estimate that salmon, the richest source of n-3 fatty acids, provides 8.2 percent of n-
3 intake (DHA plus EPA) for adults, based on USDA survey data (USDA, 2002) (2). A one 
percent change in salmon consumption should increase total n-3 intake by 8.2 percent, assuming 
n-3 intake from other sources is unchanged (3).   
While a drop in the price of salmon may also change consumption of other foods, we 
ignore such effects because we lack appropriate data (4).  Our approach may overstate the 
benefits of cheaper salmon if substitutes are rich in n-3, like mackerel, but we believe it is more 
likely to understate the benefits, because substitutes include foods high in saturated fat, like 
beef.  
Some recent reports suggest that farmed salmon is inferior to wild salmon in terms of n-
3 content (Murphy, 2003).  Our analysis of USDA data, however, suggests otherwise.   Alaska 
chums, the most important salmon species for U.S. consumers after Atlantic salmon (Welch, 
2002), have lower levels of n-3 than farmed Atlantic salmon, either raw or cooked with dry heat 
(5).  Sockeye, chinook, and pink salmon, either raw or cooked with dry heat, also have lower 
levels of n-3 in 100 gram servings than farmed Atlantic salmon  (5). In addition, both raw wild    5
  
   
Atlantic salmon and wild coho cooked with dry heat have lower n-3 levels in 100 gram servings 
than raw farmed Atlantic salmon and farmed coho cooked with dry heat respectively.  Given 
that recent epidemiological studies suggest reduced fatality risk from increased daily intake of 
n-3 (GISSI, 2002; Hu, 2002), these data suggest that farmed salmon have health benefits at least 
as large as those of wild fish.  
Consumer Response  
Empirical research suggests that a one percent decline in the price of farm-bred salmon 
leads to a one percent increase in consumption (Bjorndal et al., 1994).  We use this estimate, 
ignoring possible premiums that some consumers may be willing to pay for conventional 
salmon.     
Farming Costs And Retail Prices 
  In the absence of an appropriate, integrated model of salmon supply and demand, (6), we 
first assume simply that changes in farmers’ unit costs have a proportional effect on the price 
that farmers receive for farmed salmon.  This would be the case if salmon farming were 
competitive and had constant returns to scale, so that salmon farmers’ costs determined the 
market price of fish.  Competitive international spot markets in fact determine salmon prices 
(Abbors, 2000), and the law of one price holds for an international market with five salmon 
species (Asche et al., 1999).  
The prices that farmers receive, along with market structure and processing costs, affect 
retail prices.  In French fish markets, a one percent drop in international salmon prices lowers 
retail prices by 0.165 percent (Guillotreau et al., 2002).  This relation may be valid for the U.S.  
In 1998 in France, supermarkets, which are the predominant retail outlet in the U.S., sold nearly    6
  
   
75 percent of retailed, fresh seafood, and more than 80 percent of fresh salmon (Guillotreau et 
al., 2002). In France, 45 percent of fresh salmon was consumed in restaurants,
  where much 
salmon is also consumed in the U.S. (Reuters, 2000).   
Given this estimate, and an assumption of a perfectly competitive market for farmed 
salmon at the producer level, a one percent decrease in the cost of farmed salmon will lead to a 
.165 percent drop in the retail price of salmon.   
Conclusion 
The health effects of GM salmon are large enough to interest policy makers.  Given that 
GM salmon could lower the cost of farming salmon by half (Reuters, 2000), the preceding data 
suggest that GM salmon would reduce the risks of fatal CHD by about 0.2 percent.  Since about 
720,000 Americans aged 35 and older died from heart disease in 1999 (National Center for 
Health Statistics, 2000), a reduction of 0.2 percent amounts to about 1400 deaths per year (7).  
To characterize the uncertainty associated with this estimate we conduct a Monte Carlo 
simulation summarized in Appendix. The simulation, which does not address model uncertainty, 
shows that a 90 percent confidence interval for the number of deaths averted per year in the U.S. 
would range from 570 to 2630.  A range that reflects uncertainty in the choice of models used 
here and in underlying studies would be much larger. While these benefits seem large, they 
should be compared with the environmental risks posed by GM salmon (National Research 
Council, 2002).   
Regulators’ focus on potential adverse health effects of GM foods, without regard to 
health benefits, does not provide an adequate basis for rational policy.  Policies restricting the 
introduction of GM foods that offer lower cost access to healthier foodstuffs may    7
  
   
unintentionally curtail or postpone opportunities to improve public health. While we have 
addressed the health benefits of GM salmon, other GM foods with beneficial nutritional 
properties, such as canola oil, could offer similar benefits, if new genetic varieties lowered their 
relative price. While these types of health benefits are distinguishable from those associated 
with changes in nutritional content resulting from genetic modification, all nutrition-related 
effects should be considered in regulating GM foods.      8
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Endnotes 
 
1.  We assume  H
C
C
e e e e H C P P c c n n H
∆
≅ ∆ − − 3 3 ,       
where H, denotes the number of heart attacks in a given population over a year, C is the cost of 
producing salmon, ey x represents the percentage change in y caused by a one percent change in 
x  assuming other relevant variables are held constant, and c and P represent the intake of n-3 
fatty acids, and the retail price of salmon respectively.  This equation can be derived by 
assuming that H, n-3, c, P, and C are related through a series of nested differentiable functions. 
 
2. Alpha-linolenic acid, a third n-3 fatty acid, is not considered by Hu et al., so we do not 
consider it here.   
 
3.  Since total n-3 intake is the sum of n-3 concentrations in various foods times the amount of 
each food consumed, the percentage change in n-3 intake resulting from a one percent change in 
c is simply the share of total n-3 intake that comes from salmon, provided that substitutes to 
salmon have negligible n-3 levels. 
 
4. We are unaware of a model that integrates demand for salmon and other individual fish 
species with demand for animal products like beef, pork and chicken.  Huang, however, has 
developed an integrated analysis of prices of canned fish and other products and their effects on 
intake of polyunsaturated fatty acids and other nutrients.  Other research, (Chen et al. 2002) has 
begun to integrate economic analysis of diet and exercise with epidemiological analysis of 
health. 
 
5.  Authors’ calculations from U.S. Department of Agriculture, Economic Research Service, 
“Nutrient Data Laboratory” which can be found at http://www.nal.usda.gov/fnic/cgi-
bin/nut_search.pl 
 
6. Pascoe et al. present a model combining economic, physical and biological relationships 
among different species, but the results of three alternative scenarios differ significantly and the 
authors do not argue that one is superior.   
 
7. This estimate assumes that the effect of n-3 fatty acids on CHD estimated by Hu et al. applies 
to all men and women age 35 and older.   
 
8. We are grateful to John Morrall III, and Bob Hahn for comments and to Elisabeth Irwin for 
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Appendix 
To characterize the uncertainty in the reduction in heart attacks from the introduction of 
genetically modified salmon, we conduct a Monte Carlo simulation and estimate that a 90 % 
confidence interval for the CHD deaths averted from GM salmon would run from about 570 per 
year to 2640 per year.   Our analysis includes only the sources of uncertainty for which we have 
acceptable information about the underlying distributions.  Thus we include uncertainty in the 
health effect, the nutritional effect, the price elasticity of demand, and the effect on retail prices, 
as measured by standard errors estimates of these parameters.
1  We summarize in Table A the 
assumptions in our simulation.  We include only the uncertainty associated with our estimates of 
the relationships between n-3 and the risk of CHD fatalities and do not consider the full 
uncertainty in Hu et al’s estimates, including whether and to what extent the estimated health 
effects are applicable to men.  We also neglect uncertainty associated with whether consumers 
will respond to price declines of GM salmon as if it were untreated salmon, and the effect of 
GM salmon on the cost of fish farming. 
Our simulation implies that there is only a five percent chance that the number of deaths 
averted would be less than 570 per year, and that there is only a five percent chance that the 
deaths averted would exceed 2630 per year.
2  See Figure A. 
                                                 
1 We ignore variations in the contribution of salmon to n-3 intake because figure 1 implies it is irrelevant to determining the 
percentage change in risk. 
2 Using the @Risk software program, we run 10,000 iterations using Latin Hypercube sampling.    13
  








Variable   Estimated Value, 
Assumed Standard Deviation (), 
and Distribution. 
Percentage change in coronary heart disease fatalities 
resulting from a one percent change in n-3 fatty acid 
intake.  
e H n-3  .29 
(.084) 
normal 
Percentage change in n-3 fatty acid intake resulting from 
a one percent change in salmon consumption.   
e n-3 c  .082 
   (.009) 
normal 
Percentage change in salmon consumption resulting from 
a one percent change in the retail price of salmon.  
e c P  1 
(0.2) 
log normal 
Percentage change in the retail price of salmon resulting 
from a one percent change in the cost of salmon farming. 
e P C  .165 
(.0432) 
log normal 





Implied percentage reduction in fatal coronary heart disease, calculated 
as the product of the preceding variables.  
.00232 
Baseline incidence of fatal coronary heart disease. (Cases 
per year in the U.S.) 
H   720,000 among all adults over 35. 
Implied absolute change in annual coronary heart disease 
fatalities among adults over 35. 
H ∆   1,410, with 95 % confidence interval 
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